Nektar Therapeutics
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2016 | — | $88.1M | $59.6M |
| FY2017 | — | $87.8M | $4.8M |
| FY2018 | — | $1.72B | $194.9M |
| FY2019 | — | $1.41B | $96.4M |
| FY2020 | — | $1.08B | $199.0M |
| FY2021 | — | $679.5M | $25.2M |
| FY2022 | — | $366.6M | $88.2M |
| FY2023 | — | $131.0M | $35.3M |
| FY2024 | — | $60.7M | $44.3M |
| FY2025 | — | $89.8M | $15.1M |